Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

Cytura Therapeutics B.V.. (3/24/19). "Press Release: Cytura Therapeutics to Develop a New Class of Drugs Targeting Genomic Instability in Cancer".

Organisations Organisation Cytura Therapeutics B.V.
  Organisation 2 Thuja Capital Healthcare Fund II
  Group Thuja Capital B.V.
Products Product cancer drug
  Product 2 venture capital
Index term Index term Cytura Therapeutics–SEVERAL: investment, 201904 seed financing round led by Thuja Capital Healthcare (Seed) Fund II
Person Person van Gorp, Ad (Lead Pharma 201502 CEO + Co-founder)

Today Cytura Therapeutics announces the successful closure of a Seed financing round. The funding is provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) – KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its first proprietary small molecule program and to further expand their pipeline of new disruptive drugs, targeting genomic instability.

Cytura Therapeutics

The company will be based at the Pivot Park Life Science Campus in Oss and collaborate with the Amsterdam UMC and the Centre for Drug Design and Discovery (CD3) of the KU Leuven. Genomic instability is a major problem in cancer progression and therapy resistance. By targeting genome instability this approach could be applied both as a stand-alone as in combinations therapy. On the latter, there is a large group of patients who will at first respond to the applied therapy and later on become resistant during treatment.

“One of the biggest issues in cancer treatment is that the disease has the ability to change its nature over time caused by the increasing genomic instability. Cytura’s R&D efforts are focused on the development of small molecules that will slow down or stop this genomic instability. I am committed to find this medicine which could lead to real advancements in the fight against cancer.”
Ad van Gorp, co-founder of Cytura Therapeutics

Management and shareholders

Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Dutch Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC. In close collaboration with both organizations, Cytura Therapeutics aspires to advance it innovative first-in-class therapies targeting genomic instability of cancers.

Record changed: 2020-02-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top